Bone Density in Chronic Schizophrenia with Long-Term Antipsychotic Treatment: Preliminary Study by Lee, Tae-Young et al.
Print ISSN 1738-3684 / On-line ISSN 1976-3026
OPEN ACCESS DOI 10.4306/pi.2010.7.4.278
278  Copyright © 2010 Korean Neuropsychiatric Association  
ORIGINAL ARTICLE
Bone Density in Chronic Schizophrenia  
with Long-Term Antipsychotic Treatment: Preliminary Study 
Tae-Young Lee
1, Moon-Yong Chung
2 , Hae-Kyung Chung
2, 
Jin-Hee Choi
2, Tae-Yong Kim
2 and Hyung-Seok So
2
1National Naju Hospital, Naju, Korea 
2Department of Psychiatry, Seoul Veterans Hospital, Seoul, Korea
ObjectiveaaDecreased bone mineral density has been found in the chronic schizophrenic patients who have been given a long-term 
administration of antipsychotics. Hyperprolactinemia from the antipsychotics and the negative symptom of schizophrenia were consid-
ered as the causes for this finding. In this study, the effect of hyperprolactinemia and the negative symptom of schizophrenia on bone 
mineral density was investigated on male schizophrenic patients.
MethodsaaThe cross-sectional study was carried out with the subjects of 45 male schizophrenic patients who have undertaken the 
monotherapy with risperidone, olanzapine and clozapine for at least one year. The demographic factors, clinical symtoms, bone mineral 
density and hematological test were examined for all the subjects.
ResultsaaNo significant relationship was found between hyperprolactinemia and the decreased bone mineral density in the subjects. 
The negative schizophrenia symptom of the subjects showed a significant effect on the decreased bone mineral density.
ConclusionaaThe decreased bone mineral density finding in the male schizophrenic patients may be caused by the negative schizo-
phrenia symptom rather than the hyperprolactinemia due to the antipsychotics. Additional studies are further required regarding other 
factors that may affect the decreased bone mineral density such as activity, calcium intake and exposure to sunlight.   
  Psychiatry Investig 2010;7:278-284
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INTRODUCTION
Osteoporosis is a disease that happens when the bone ma-
trix, which is the base of bone growth, is produced insufficient-
ly or when calcium decreases considerably in bone and, as a 
result, bone mineral density decreases.
1 Bone mineral density 
is affected by the peak bone mineral density predetermined 
genetically, but it is also affected by various other factors. That 
is, it is lower in women, those in their puberty, those whose 
menarche has been delayed and those with premature meno-
pause, and it is influenced by insufficient calcium intake, lack of 
exercise, excessive smoking, alcohol or caffeine abuse, etc.
2-4 
In the United States, Osteoporosis increases the risk of bone 
fracture, and the incidence is increasing every year, as there 
were 1,300,000 cases in 1990 but there are expected to be 
2,600,000 cases in 2025.
5,6 Patients with schizophrenia have 
many risk factors of osteoporosis because of their inadequate 
eating habits, low activity, polydipsia, excessive smoking, al-
cohol abuse, etc.
7 In addition, the risk of bone fracture can be 
heightened both by orthostatic hypotension caused by drugs 
and by falls caused by dizziness.
8
There have been several reports that the decrease of bone 
mineral density is observed in patients with chronic schizo-
phrenia.
9-11 Early research suggested that such a decrease might 
be related to polydipsia or serum calcium concentration, but 
it could produce no significant correlation with the decrease 
of bone mineral density.
12,13 On the contrary, osteoporosis or 
osteopenia was observed in around 80% of the patients with 
a prolactin-secreting tumor, and the change of sex hormones 
caused by hyperprolactinemia was believed to be related to the 
decrease of bone mineral density.
14,15 This suggests that hyper-
prolactinemia and the following change of sex hormones ob-
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served in patients with chronic schizophrenia may be related to 
the decrease of bone mineral density. 
There have been many reports that hyperprolactinemia hap-
pens in patients with chronic schizophrenia who have taken 
typical antipsychotics and risperidone for a long period in the 
past, and the decrease of bone mineral density is observed in 
such patients.
16-18 The incidence was greater among the female 
menopausal patients who underwent a drastic change in sex 
hormones. On the other hand, there were also reports that 
there was no significant correlation between the prolactin con-
centration and bone mineral density in a group of patients who 
used typical antipsychotics for a long time, and the factors 
causing the decrease of bone mineral density in such patients 
were lack of calcium intake, eating disorder, lack of sunlight ex-
posure and insufficient exercise due to the negative symptom 
rather than the effect of prolactin.
19,20 As such, it is quite contro-
versial to claim whether the decrease of bone mineral density 
observed in schizophrenic patients is caused by antipsychotics.
Thus, this study was performed in order to determine wheth-
er the decrease of bone mineral density observed in male 
schizophrenic patients who have taken antipsychotics for a 
long period, and are less influenced by a change of sex hor-
mones as in menstruation or menopause, is caused by hyperp-
rolactinemia resulting from the antipsychotics or by negative 
symptoms that may result in the risk factors of osteoporosis 
such as lack of calcium intake, eating disorder, lack of sunlight 
exposure or lack of exercise.
METHODS
Subjects
This study was carried out with 20-year-old or older patients 
who were under treatment as outpatients or inpatients at the 
Psychiatric Department of Seoul Veterans Hospital from 
March 1, 2007 to June 30, 2007. The patients were limited to 
the men who had been diagnosed with schizophrenia through 
the review of medical records by DSM-IV and clinical inter-
views by a psychiatrist and a resident, and who had used only 
one drug among risperidone, olanzapine or clozapine for the 
previous one year or longer. 
Criteria for exclusion are as follows: 1) those with a history 
of alcohol or other substance dependence or abuse; 2) those 
with a serious internal disease that may affect bone mineral 
density; 3) those with a history of bone fracture within one 
year; 4) those with diseases or symptoms that can impair 
physical mobility, including Parkinson’s disease and extrapy-
ramidal side effects; 5) those with another accompanying dis-
ease in Axis I according to DSM-IV; and 6) those who were 
taking a mood stabilizer, antidepressant or anxiolytic that 
can affect bone mineral density in addition to the antipsy-
chotic. Each of the subjects provided a written consent for 
their participation in the present study after being informed 
about the objective of this study. 
Methods
The clinical information of all the subjects, including the de-
mographic information and drug treatment history, were col-
lected by the medical records review and physical examination 
and their clinical symtoms were assessed based on the Positive 
and Negative Symptoms Scales (PANSS). The antipsychotic 
doses of risperidone 1 mg, olanzapine 2.5 mg and clozapine 50 
mg were converted to chlorpromazine 100 mg, which is an 
equivalent dose. 
The bone mineral density T-score and Z-score of the subject 
group were measured with dual-energy X-ray absorptiome-
try (DEXA; hologic discovery W). The bone mineral density 
was measured at the lumbar spine L1-L4, the femoral neck, the 
trochanteric regions of the left hip and the intertrochanteric 
regions of the left hip. 
Blood samples were taken from all the subjects at 8 o’clock in 
the morning at the Department of Clinical Laboratory in the 
hospital, and using the samples, we measured hormones that 
Table 1. Demographic and clinical data of risperidone and olanzapine and clozapine groups
Characteristic
Risperidone (N=20) Olanzapine (N=15) Clozapine (N=10) Total (N=45)
p-value
Mean±SD Mean±SD Mean±SD Mean±SD
Age (years) 047.9±9.5 053.5±14.6 046.8±6.1 049.5±11.1 0.23
Duration (years) 023.8±8.8 027.3±11.3 022.6±6.9 024.7±9.3 0.40
BMI 025.7±2.9 026.6±1.91  027.3±2.2 026.4±2.5 0.26
Dosage (mg/day) 252.5±74.8 273.7±83.7 265.0±35.7 280.1±71.0 0.56
PANSS
Positive subscale 016.3±2.9 018.5±3.3 017.7±2.6 017.3±3.0 0.11
Negative subscale 020.6±3.4 019.6±4.5 018.8±3.5 019.8±3.8 0.48
Duration: duration of illness, BMI: body mass index, Dosage: chlorpromazine equivalent dosage, PANSS: Positive and Negative Symptoms 
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may affect bone metabolism including serum estradiol, proges-
terone, testosterone, follicle-stimulating hormone (FSH), lu-
teinizing hormone (LH), thyroid hormones [ex. triidothyro-
nine (T3), free thyroxine (fT4), thyroid stimulating hormone 
(TSH)], prolactin and cortisol. In addition, bone markers such 
as plasma bone alkaline phosphatase, osteocalcin, C-terminal 
telopeptide type I collagen (ICTP), urinary calcium and phos-
phorus were measured. The study protocol was approved by 
the institutional review board at Seoul Veterans Hospital.
Statistical analysis
A one-way analysis of variance was performed in order to 
compare demographical characteristics, the mean values of 
the test results such as PANSS, Body Mass Index (BMI) and 
blood prolactin concentration, with that of the bone mineral 
density level among the subject groups. Pearson’s rank corre-
lation analysis was performed on all the patients to determine 
the correlations among the parameters, and based on these re-
sults, a multivariate regression analysis was performed with 
the variables that have significant correlations with each corre-
sponding bone and identify the factors that significantly affect 
bone mineral density. 
In addition, a chi-square test was performed to see whether 
osteoporosis or osteopenia are more frequently examined in a 
specific drug. The data were analyzed using SAS Version 8.1, 
and the statistical significance was determined based on the 
significance level of p<0.05.
RESULTS
Comparision of the patients’ demographical and
clinical characteristics
A total of 45 patients, including 20 in the risperidone group, 
15 in the olanzapine group and 10 in the clozapine group, par-
ticipated in this study. All of them completed the study. There 
was no significant difference among the three groups in aver-
age age, disease duration, the chlorpromazine equivalent dos-
age of antipsychotic and the positive sub-scale and negative 
sub-scale of PANSS (Table 1).
Comparison of the laboratory and radiologic 
examination results in each patient group
In the laboratory test performed for each patient group, no 
significant difference was found in serum estrogen, progester-
one, testosterone, FSH, LH, T3, fT4, TSH, cortisol, bone, alka-
line phosphatase, osteocalcin, ICTP, urinary calcium and phos-
phate. The serum prolactin concentration of the risperidone 
group was significantly higher than that of the clozapine group 
(Table 2). In the results of radiologic examination, bone miner-
al density Z-score was not significantly different among the 
subject groups (Table 3). In the risperidone group, 15 out of the 
20 subjects had hyperprolactinemia, in addition to 3 subjects 
with osteoporosis and 3 subjects with osteopenia. In the olan-
zapine group, 6 among the 15 subjects had hyperprolactinemia, 
and 7 subjects had osteopenia. Among the 10 subjects in the 
Table 2. Laboratory data of risperidone and olanzapine and clozapine groups
Characteristic
Risperidone (N=20) Olanzapine (N=15) Clozapine (N=10) Total (N=45)
p-value
Mean±SD Mean±SD Mean±SD Mean±SD
Estrogen (pg/mL) 27.3±8.8 35.4±13.3 23.3±16.3 29.1±12.9 0.05
Progesterone (ng/mL) 00.8±0.2 02.7±6.8 01.7±2.0 01.7±4.0 0.41
Testosterone (ng/mL) 03.5±2.2 04.1±2.1 04.1±1.3 03.8±2.0 0.56
LH (mIU/mL) 06.1±3.2 07.1±3.5 05.7±1.7 06.3±3.1 0.48
FSH (mIU/mL) 06.8±4.4 07.6±5.1 05.2±2.8 06.7±4.3 0.38
T3 (ng/mL) 01.0±0.2 01.1±0.2 01.0±0.2 01.1±0.2 0.33
fT4 (ng/dL) 01.3±0.3 01.3±0.2 01.2±0.3 01.3±0.3 0.33
TSH (uIU/mL) 02.7±2.1 02.2±1.3 01.6±0.8 02.3±1.6 0.24
Prolactin (ng/mL) 33.3±17.1 21.8±17.6 10.5±9.4 24.4±18.1 0.00**
Cortisol (ug/dL) 13.4±4.3 13.8±4.8 12.7±6.0 13.3±4.8 0.85
ALP (ug/L) 21.0±13.9 17.3±6.1 16.4±4.4 18.8±10.2 0.42
Osteocalcin (ng/mL) 20.2±7.5 18.2±6.4 15.6±4.8 18.5±6.7 0.20
ICTP (ug/L) 00.4±1.0 00.3±0.2 00.2±0.1 00.3±0.2 0.10
Calcium (mg/dL) 07.2±5.7 12.9±9.5 09.4±8.7 09.6±8.0 0.11
Phosphorus (mg/dL) 15.7±13.2 22.2±15.0 19.3±16.3 18.7±14.5 0.43
**p<0.05. LH: luteinizing hormone, FSH: follicle stimulating hormone, ALP: serum bone alkaline phosphatase, ICTP: cross-linked C-termi-
nal telopeptide of type I collagenTY Lee et al. 
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clozapine group, 1 subject had hyperprolactinemia and 1 sub-
ject had osteopenia. We analyzed whether a specific drug is 
more related to osteopenia or osteoporosis, but no significant 
difference was observed among the 3 drugs.
Correlation and regression analysis among 
demographic variables, laboratory variables and 
bone mineral density 
We analyzed the correlation between the major variables that 
are likely to affect bone metabolism, including bone markers 
and bone mineral density Z-score (Table 4). With respect to 
the correlations with bone mineral density, the average age 
was in a negative correlation with bone mineral density in the 
femoral neck, the trochanteric regions of the left hip and the 
intertrochanteric regions of the left hip; the disease duration 
was in a negative correlation with bone mineral density in the 
lumbar spine L2, the femoral neck, the trochanteric regions 
of the left hip and the intertrochanteric regions of the left hip; 
the BMI was in a positive correlation with bone mineral den-
sity in the lumbar spine L3, the femoral neck and the tro-
chanteric regions of the left hip; and the sub-scale of negative 
symptoms was in a nega tive correlation with bone mineral 
density in the lumbar spine L1-3, the femoral neck, the tro-
chanteric regions of the left hip and the intertrochanteric re-
gions of left hip. In addition, the FSH was in a negative corre-
lation with bone mineral density in the trochanteric regions of 
the left hip and the trochanteric regions of the left hip; the LH 
was in a negative correlation with bone mineral density in the 
femoral neck, the trochanteric regions of left hip and the in-
tertrochanteric regions of left hip; and the C-terminal telo-
peptide was in a negative correlation with the lumbar spine 
L1, 3 and 4. Besides, no significant correlation was observed 
between other laboratory findings and bone mineral density. 
The correlation between hyperprolactinemia and bone min-
eral density was analyzed only with the 22 patients with hy-
perprolactinemia over all the subject groups, but no significant 
correlation was found. Based on these results, a multivariate 
regression analysis was performed with the variables that have 
significant correlations with each corresponding bone includ-
ing age, disease duration and BMI of the subjects. The results 
showed that bone mineral density in the lumbar spine L1 
was significantly affected by the sub-scale of negative symp-
toms (p=0.02) and C-terminal telopeptide (p=0.02); in the 
lumbar spine L2 by disease duration (p=0.02) and the sub-
Table 4. Correlations coefficients among major variables in all subjects
Lumbar 1 Lumbar 2 Lumbar 3 Lumbar 4 Femoral Trochanteric Intertrochanteric
Age 0.2083 0.0546 0.1354 0.3886 0.0410* 0.2127 0.0396*
Duration 0.1343 0.0286* 0.1117 0.3200 0.0019** 0.0541 0.0196*
BMI 0.0813 0.0194* 0.0265* 0.0652 0.0471* 0.0290* 0.0783
Negative subscale 0.0277* 0.0373* 0.0446* 0.0558 0.0143* 0.0131* 0.0071**
Prolactin 0.1858 0.7663 0.2452 0.5518 0.7985 0.9176 0.8155
FSH 0.0874 0.1130 0.1178 0.2522 0.0594 0.0212* 0.0354*
LH 0.1984 0.1079 0.0795 0.0959 0.0273* 0.0358* 0.0047**
ICTP 0.0205* 0.0569 0.0211* 0.0320* 0.6665 0.0552 0.1238
Pearson correlations coefficients. *p<0.05, **p<0.01. Lumbar: lubmar spine, Femoral: femoral neck of left hip, Trochanter: trochanteric re-
gions of left hip, Intertrochanter: intertrochanteric regions of left hip, Duration: duration of illness, BMI: body mass index, LH: luteinizing 
hormone, FSH: follicle stimulating hormone, ICTP: cross-linked C-terminal telopeptide of type I collagen 
Table 3. Bone mineral density Z score data of risperidone and olanzapine and clozapine groups
BMD (Z score)
Risperidone (N=20) Olanzapine (N=15) Clozapine (N=10) Total (N=45)
p-value
Mean±SD Mean±SD Mean±SD Mean±SD
Lumbar 1 0.25±0.99 0.46±0.88 1.01±0.84 0.49±0.95 0.12
Lumbar 2 0.36±1.00 0.68±1.08 0.90±0.78 0.58±0.99 0.34
Lumbar 3 0.24±0.90 0.42±1.05 0.46±0.86 0.34±0.93 0.79
Lumbar 4 -0.05±0.94 0.33±0.94 0.08±1.00 0.10±0.95 0.50
Femoral 0.25±0.88 0.17±0.80 0.55±0.75 0.19±0.83 0.27
Trochanter -0.23±0.88 0.16±0.84 0.34±0.80 0.02±0.86 0.18
Intertrochanter 0.08±0.92 0.13±0.85 0.84±1.17 0.26±0.86 0.11
Lumbar: lubmar spine, Femoral: femoral neck of left hip, Trochanter: trochanteric regions of left hip, Intertrochanter: intertrochanteric re-
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scale of negative symptoms (p=0.03); in the lumbar spine L3 
by C-terminal telopeptide (p=0.02); in the lumbar spine L4 
by C-terminal telopeptide (p=0.03); in the femoral neck by the 
average age (0.04) and disease duration (p=0.00); in the tro-
chanteric regions of the left hip by the sub-scale of negative 
symptoms (p=0.02); and in the trochanteric regions of the left 
hip by the sub-scale of negative symptoms (p=0.03).
DISCUSSION
Typical antipsychotics or risperidone blocks the dopamine 
D2 receptor of lactotrophs in the anterior pituitary and the pro-
lactin secretion inhibiting function, and consequently, causes 
hyperprolactinemia.
21,22 Hyperprolactinemia directly inhibits 
osteoblast or hinders the action of LH or FSH, and thus causes 
a decrease of estrogen concentration.
23,24
Women’s bone mineral density is highest during the period 
from the early 30s to the mid 30s, and then decreases slowly, 
and the decrease is accelerated for 3 to 5 years from the begin-
ning of menopause, and after that, it decreases by 1.0 to 1.5% a 
year.
25,26 Menopause accelerates bone loss due to the effect of 
decrease in sex hormones. Estrogen decreases bone loss by 
inhibiting the function of osteoclast, and progesterone acceler-
ates bone formation by stimulating osteoblast.
27,28 Thus, the de-
crease of sex hormones by hyperprolactinemia accelerates the 
decrease of bone mineral density.
Patients with chronic schizophrenia actually show a very high 
prevalence of osteoporosis and bone fracture compared to nor-
mal people, and there have been many reports that bone min-
eral density decreased markedly in them.
29 Hence, there have 
been many studies that presumed a correlation between the 
decrease of bone mineral density found in patients with chron-
ic schizophrenia and hyperprolactinemia caused by long-term 
medication with antipsychotics. 
In a study of chronic schizophrenic patients whose average 
age was 43, Abraham et al.
30 reported a significant negative cor-
relation between antipsychotic-induced hyperprolactinemia 
and bone mineral density and explained that this mechanism 
is the same as that of the bone mass decrease found in patients 
with prolactin-secreting adenomas. In addition, Naidoo et al.
31 
conducted a short survey on the potential impact of antipsy-
chotics agents and reported that elevated rates of osteoporosis 
and pathological fractures were observed in schizophrenic pa-
tients treated with antipsychotics for a long period, and they 
might have been caused primarily by hyperprolactinemia in-
duced by antipsychotics and secondarily by the lower estrogen 
and testosterone levels.
 
However, such a mechanism may not be applied to all the 
cases since the subjects of many studies in the past were fe-
male schizophrenic patients and the effect of sex hormones 
on the decrease of bone mineral density is different in male 
schizophrenia patients.
Meanwhile, there have also been reports that the decrease of 
bone mineral density observed in chronic schizophrenic pa-
tients medicated with antipsychotics for a long-term period is 
caused by the negative symptoms of schizophrenia itself rath-
er than by the drugs. Abraham et al.
32 reported that higher rates 
of bone formation and resorption were observed in the schizo-
phrenic patients with decreased bone mineral density, but there 
was no significant correlation between serum prolactin and bone 
mineral density. Rather, they reported that the common nega-
tive symptoms in chronic schizophrenic patients were related 
to the decrease of bone mineral density. In addition, Hummer 
et al.
33 reported that the decrease of bone mineral density ob-
served in patients with chronic schizophrenia was not corre-
lated with hyperprolactinemia, and it was more reasonable to 
consider it as a result of the patients’ negative symptoms.
In this study, the sex hormone concentration of all the pa-
tients fell within the normal range and no significant correla-
tion was found between sex hormones and the decrease of 
bone mineral density or between prolactin and the decrease of 
bone mineral density. These results are different from the pre-
vious studies, which concluded that hyperprolactinemia ob-
served in schizophrenic patients may directly cause a decrease 
of bone mineral density or that the reduction of sex hormone 
levels induced by hyperprolactinemia may cause a decrease of 
bone mineral density, suggesting that the pathophysiology of 
the decreased bone mineral density found in the male schizo-
phrenic patients may be different from that of females.
Generally, men have a higher level of peak bone density than 
women, and this prevents the exacerbation of osteoporosis.
34 
In addition, both testosterone and estrogen act as resistance 
factors for the decrease of bone density; however, while the con-
centration of estrogen in the blood of women rapidly drops af-
ter menopause, the concentration of testosterone in the blood 
of men declines gradually.
35 Young Caucasian women appear 
to be particularly vulnerable to developing hyperprolactinae-
mia and the associated hypogonadism and bone loss. The oc-
currence of menstrual dysfunction should alert clinical suspi-
cions of hyperprolactinaemia and bone de-mineralisation.
36 
Meanwhile, the age of onset of schizophrenia for men is gener-
ally lower than for women. In other words, at the same age 
range, male patients with schizophrenia could have longer pe-
riods to contract the disease in comparison to female patients 
with schizophrenia. Moreover, early onset of the disease can in-
fluence the peak bone density.
37 Since there are too many fac-
tors involved in the decrease of bone density in pathophysiol-
ogy that relate to the differences between men and women, it is 
extremely difficult to discern contributions of individual fac-
tors. Accordingly, a future study is required on whether the de-TY Lee et al. 
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crease of bone density among male schizophrenics occurs due 
to different mechanisms in comparison to female patients by 
controlling the factors. 
On the other hand, when significant factors affecting the de-
crease of bone mineral density in the subject groups were in-
vestigated by including the factors which are known to cause a 
decrease of bone mineral density, it was found that the negative 
symptoms scale of PANSS and the blood concentration of ICTP 
have a significant effect on the decrease of bone mineral densi-
ty. In addition, the risperidone group showed a significantly 
higher blood prolactin level than the olanzapine group and the 
clozapine group, but the rate of observed osteomalacia or os-
teoporosis was not significantly different among the 3 groups. 
These results support the hypothesis that the decrease of bone 
mineral density observed in schizophrenic patients medicated 
with antipsychotics for a long period could be caused more by 
the negative symptoms of schizophrenia than by the drugs. 
Among the causes of the decrease of bone mineral density, 
factors that can be correlated with the negative symptoms of 
PANSS include lack of load-bearing exercise due to a decrease 
in activities, deficiency in Vitamin D metabolism due to lack of 
sunlight exposure and lack of calcium intake due to eating prob-
lems.
38,39 
Vitamin D can be taken partially from food, but it is mostly 
generated as provitamin D in the body reacts to ultraviolet rays 
on the skin’s surface and is converted to vitamin D.
40 For the 
generation of vitamin D, indoor sunlight transmitted through 
the window is insufficient, and the outdoor ultraviolet wave-
length is important.
41 In addition, because bone cells grow as 
they are stimulated by the pressure of gravity, light exercise is 
important to produce such an effect.
42 
However, chronic schizophrenic patients with severe nega-
tive symptoms cannot have sufficient outdoor activities, and 
this results in the lack of load-bearing exercise. Therefore, in 
combination with lack of calcium intake, factors such as lack of 
exposure to ultraviolet rays and lack of load-bearing exercise 
lower the growth of bone cells and increase bone reabsorption, 
and thus cause the decrease of bone mineral density. 
However, the risk factors can be caused by positive symp-
toms, including delusion or hallucination of patients with 
schizophrenia. Moreover, a study on whether inherent patho-
physiology of negative symptoms directly affects the decrease 
of bone density is still lacking. Against this backdrop, we rec-
ommend an even more controlled study on whether the de-
crease of bone density is incurred by risk factors caused by neg-
ative symptoms of patients with schizophrenia or by another 
pathophysiology. Serum bone specific alkaline phosphatase 
and osteocalcin, the bone formation markers, were within the 
normal range in all of the subject groups, and they did not show 
a significant correlation with bone mineral density. However, 
bone absorption marker, c-terminal telopeptides type I collagen, 
increased in the subject groups and had a significant effect on 
the decrease of bone mineral density in the lumbar spine L1, 3 
and 4. 
Continuous bone turnover takes place in the skeleton as old 
bone is removed by bone absorption and new bone is generat-
ed by bone formation. However, while it takes at least 3 to 4 
years to determine the change of bone mineral density through 
radiologic examination, biochemical bone markers allow more 
sensitive tests through which the change of bone metabolism 
can be assessed in a relatively short time.
43 Various biochemical 
bone markers have been known, but DPD, NTX and CTX are 
most recommended as bone adsorption markers, and BSALP 
and OC as bone formation markers.
44 In this study, the increase 
of ICTP had a significant effect on the decrease of bone mineral 
density in the lumbar spine L1, 3 and 4, whereas other bone 
markers were not correlated with the decrease of bone miner-
al density in the patient groups. ICTP has a low specificity in 
reflecting bone absorption, since it can be generated by the de-
composition of not only bone but also other collagen.
45,46 Thus, 
it should be understood that the decrease of bone mineral den-
sity is correlated more with physical changes causing the in-
crease of ICTP than with the increase of ICTP itself.
The limitations of this study are as follows: First, the subjects 
of this study were limited to male patients. In previous studies, 
the decrease of bone mineral density was more frequently 
found in female schizophrenic patients than in male schizo-
phrenic patients, which suggests that sex hormones play an im-
portant role in the decrease of bone mineral density. Thus, the 
results of this study should be carefully interpreted. Second, be-
cause sunlight exposure, amount of physical exercise and oral 
calcium intake were not controlled by the subject groups, it was 
not verified whether the negative symptoms found in the subject 
groups are directly correlated with such factors or not. Third, 
there might have been a difference in the amount of activities 
depending on the environment of the subject groups that in-
cluded inpatients and outpatients, but such a factor was not 
controlled. Fourth, there was no comparison of the result to a 
control group of schizophrenic patients who did not take anti-
psychotics. 
This study investigated the decrease of bone mineral density 
in male schizophrenic patients who had taken one drug among 
risperidone, olanzapine or clozapine for a long period of time. 
The results showed that the prolactin concentration did not have 
a significant effect on bone mineral density in the patient groups, 
and the negative sub-scale of PANSS had a significant effect on 
the decrease of bone mineral density. Therefore, follow-up re-
search with suchlike patient groups needs to be conducted 
while controlling factors such as negative symptoms, exposure 
to sunlight, calcium intake and amount of excercise.284  Psychiatry Investig 2010;7:278-284
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